Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients
ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIB. The additi ...
Yahoo Finance6d
Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients
Researchers used the Parsortix ® system to isolate and harvest CTCs from 30 patients with EGFR-mutated NSCLC that were undergoing treatment with osimertinib (TAGRISSO: AstraZeneca). Osimertinib ...
Finanznachrichten5d
Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients
DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIB The addition of CTC-DNA analysis to clinical trials ...
Pharmabiz3d
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
News Medical on MSN2d
Scientists map cancer mutations in EGFR gene, revealing drug resistance paths
Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...
Positive Outlook for Nuvectis Pharma: Promising Clinical and Preclinical Developments Justify Buy Rating
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Nuvectis Pharma (NVCT – Research Report) today and set a price target ...
Managed Healthcare Executive4d
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for ...